000 | 01849 a2200529 4500 | ||
---|---|---|---|
005 | 20250514155044.0 | ||
264 | 0 | _c20031106 | |
008 | 200311s 0 0 eng d | ||
022 | _a0008-5472 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _avan Ojik, Heidi H | |
245 | 0 | 0 |
_aCpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. _h[electronic resource] |
260 |
_bCancer research _cSep 2003 |
||
300 |
_a5595-600 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
650 | 0 | 4 |
_aAdjuvants, Immunologic _xpharmacology |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntibodies, Bispecific _ximmunology |
650 | 0 | 4 |
_aAntibodies, Monoclonal _ximmunology |
650 | 0 | 4 |
_aAntibody-Dependent Cell Cytotoxicity _xdrug effects |
650 | 0 | 4 |
_aCell Division _xdrug effects |
650 | 0 | 4 |
_aCpG Islands _ximmunology |
650 | 0 | 4 | _aDrug Synergism |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aGranulocytes _xdrug effects |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImmunization, Passive _xmethods |
650 | 0 | 4 |
_aImmunoglobulin G _ximmunology |
650 | 0 | 4 |
_aKiller Cells, Natural _xdrug effects |
650 | 0 | 4 |
_aLymphoma _ximmunology |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Inbred BALB C |
650 | 0 | 4 | _aMice, Inbred C3H |
650 | 0 | 4 | _aMice, Inbred C57BL |
650 | 0 | 4 |
_aOligonucleotides _ximmunology |
650 | 0 | 4 |
_aReceptor, ErbB-2 _ximmunology |
650 | 0 | 4 |
_aReceptors, IgG _xbiosynthesis |
650 | 0 | 4 | _aUp-Regulation |
700 | 1 | _aBevaart, Lisette | |
700 | 1 | _aDahle, Christopher E | |
700 | 1 | _aBakker, Annie | |
700 | 1 | _aJansen, Marco J H | |
700 | 1 | _avan Vugt, Martine J | |
700 | 1 | _avan de Winkel, Jan G J | |
700 | 1 | _aWeiner, George J | |
773 | 0 |
_tCancer research _gvol. 63 _gno. 17 _gp. 5595-600 |
|
999 |
_c14261776 _d14261776 |